459회 전남대학교

459회 

연사:  이제중 박사

제목: Immunotherapy Using Dendritic Cells against Multiple

       Myeloma: How to improve?

Abstract 

 Multiple myeloma (MM) is a clonal B-cellhematologic malignancy that has remained essentially incurable with conventional therapy. Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic modality to treat MM. DC-based idiotype vaccination was recently suggested to induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and the clinical effectiveness of such vaccinations in MM still needs to be proven. DC-based therapies in MM may need to be “boosted” with other tumor-specific antigens and potent DCs may be needed to increase the effectiveness of treatment against MM. Fully mature DCs with both high migratory character and high cytokine production are very important for effective DC-based cancer vaccination to induce high numbers of Th1-type CD4⁺ T cells and CD8⁺ CTLs. The conventional or standard dendritic cells (sDCs), induced byconventional cytokine cocktail of  TNF-a, IL-1b, IL-6, and PGE₂, are known to favor an effective migration toward lymph nodes, but can mediate Th2 polarization and promote DCs to secrete the immunosuppressive cytokines, such as IL-10. In addition, these DCs do not induce effectively the Th1-type response because PGE₂ abolishes the secretion of IL-12p70 in response to CD40L-stimulation. Several investigators, including our group, tried to develop the potent DCs having a capacity of high IL-12p70 production and high migratory character for inducing effective tumor-specific immune responses. In this meeting, I would like to discuss our recent lab works for DC translational research in the field of MM and future perspective with participants at the seminar.